


ProtoKinetix, Inc. (PKTX)

None; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001128189

ProtoKinetix, Inc. PKTX; healthcare		
Grade	None 2 of 14 inputs computable; 7 are required	
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$483,374	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	late filer, thin data, degenerate inputs not computable: dilution, short runway, distress, fortress balance sheet	
Inputs computable	2 of 14	
Graded from	filings received through Sep 3, 2026 36 days before the rescan; latest periodic filing 10-K received Sep 3, 2026	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Sep 3, 2026

"we," "us," "our," or the "Company") is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGPs®. The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGPs® in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP® to market. Inc.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 8.0						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(54.4%)	(6.6%)	8.0	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2025-12-31
Altman Z double-prime		not computable	(0.31)			required facts have no common fiscal period end
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		not computable	2.96x			current liabilities must exceed \$100,000
Growth and financing, sleeve percentile 48.4						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 3
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 0
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		1.5%	2.1%	48.4	704	2025-12-31
Net share issuance, one year		not computable	2.5%			prior share count is 523 days earlier

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 3 NT 10-K/Q filings in the last eight quarters

Thin data	2 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-09 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	not computable	8.0%	
Distance from 52-week high	not computable	(31.4%)	
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.28	
Sales to price	not computable	0.31	
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	not computable	(0.14)	

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	36 (10-K received Sep 3, 2026)
Median daily dollar volume, 63 sessions	n/a

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$393,650	2025-12-31	2026-09-03	10-K	0001079973-26-001218
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$135,377	2025-12-31	2026-09-03	10-K	0001079973-26-001218
3	assets	us-gaap:Assets	\$483,374	2025-12-31	2026-09-03	10-K	0001079973-26-001218
4	assets	us-gaap:Assets	\$466,137	2024-12-31	2026-09-03	10-K	0001079973-26-001218
5	operating income	us-gaap:OperatingIncomeLoss	-\$916,933	2011-12-31	2014-04-30	10-K	0001062993-14-002480
6	interest expense	us-gaap:InterestExpense	\$12,000	2011-12-31	2014-04-30	10-K	0001062993-14-002480
7	current assets	us-gaap:AssetsCurrent	\$21,458	2023-12-31	2024-03-20	10-K	0001079973-24-000403
8	current liabilities	us-gaap:LiabilitiesCurrent	\$44,696	2023-12-31	2025-03-28	10-K	0001079973-25-000516
9	revenue	us-gaap:Revenues	\$0	2014-12-31	2015-04-14	10-K	0001079973-15-000278
10	revenue	us-gaap:Revenues	\$0	2013-12-31	2015-04-14	10-K	0001079973-15-000278
11	revenue	us-gaap:Revenues	\$0	2011-12-31	2014-04-30	10-K	0001062993-14-002480
12	assets	us-gaap:Assets	\$480,557	2023-12-31	2025-03-28	10-K	0001079973-25-000516
13	assets	us-gaap:Assets	\$462,870	2022-12-31	2024-03-20	10-K	0001079973-24-000403
14	shares outstanding	dei:EntityCommonStockSharesOutstanding	411,630,152	2026-09-02	2026-09-03	10-K	0001079973-26-001218
15	shares outstanding	dei:EntityCommonStockSharesOutstanding	377,580,152	2025-03-28	2025-03-28	10-K	0001079973-25-000516